Corrigendum to “Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer”[Canc. Lett. 369 (2015) 58–66] (Cancer Letters (2015) 369(1) (58–66), (S0304383515005169), (10.1016/j.canlet.2015.06.028));Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer

Cancer Letters

Volumn 369, Issue 1, 2015, Pages 58-66

  Liu, Yanfang ^a,b   Zhang, Xin ^c   Zhang, Yujing ^d   Hu, Zunqi ^c   Yang, Dejun ^c   Wang, Changming ^c   Guo, Meng ^c   Cai, Qingping ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d 309TH HOSPITAL OF PLA   (China)

Author keywords

Apoptosis; Gastric cancer; MicroRNA; MiRNomes; Therapy

Indexed keywords

MICRORNA; MICRORNA 133 3P; MICRORNA 133A; MICRORNA 133B; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; BCL2L1 PROTEIN, HUMAN; HISTONE; MCL1 PROTEIN, HUMAN; MIRN133 MICRORNA, HUMAN; PROTEIN BCL X;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE MAPPING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN GENOME; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MIRNOME; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA EXTRACTION; STOMACH CARCINOMA; TRANSCRIPTION REGULATION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BINDING SITE; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HEK293 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BASE SEQUENCE; BCL-X PROTEIN; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC THERAPY; HEK293 CELLS; HISTONES; HUMANS; MICE, NUDE; MICRORNAS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE; STOMACH NEOPLASMS; TUMOR BURDEN;

EID: 84943454602     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2020.07.016     Document Type: Erratum

References (33)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin 2013, 63:11-30.
3. Choi I.S., Wu T.T. Epigenetic alterations in gastric carcinogenesis. Cell Res 2005, 15:247-254.
4. McLean M.H., El-Omar E.M. Genetics of gastric cancer. Nat. Rev. Gastroenterol. Hepatol 2014, 11:664-674.
5. Wadhwa R., Song S., Lee J.S., Yao Y., Wei Q., Ajani J.A. Gastric cancer-molecular and clinical dimensions. Nat. Rev. Clin. Oncol 2013, 10:643-655.
6. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
7. Baumjohann D., Ansel K.M. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat. Rev. Immunol 2013, 13:666-678.
8. Roberts A.P., Jopling C.L. Targeting viral infection by microRNA inhibition. Genome Biol 2010, 11:201.
9. Song S., Ajani J.A. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat. Rev. Gastroenterol. Hepatol 2013, 10:109-118.
10. Hansen T.B., Kjems J., Damgaard C.K. Circular RNA and miR-7 in cancer. Cancer Res 2013, 73:5609-5612.
11. Mulrane L., McGee S.F., Gallagher W.M., O'Connor D.P. miRNA dysregulation in breast cancer. Cancer Res 2013, 73:6554-6562.
12. Blahna M.T., Hata A. Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr. Opin. Cell Biol 2013, 25:233-240.
13. Lovat F., Valeri N., Croce C.M. MicroRNAs in the pathogenesis of cancer. Semin. Oncol 2011, 38:724-733.
14. Moltzahn F., Olshen A.B., Baehner L., Peek A., Fong L., Stoppler H., et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011, 71:550-560.
15. Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr. Biol 2002, 12:735-739.
16. Yu H., Lu Y., Li Z., Wang Q. microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer. Curr. Drug Targets 2014, 15:817-828.
17. Chen J.F., Mandel E.M., Thomson J.M., Wu Q., Callis T.E., Hammond S.M., et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet 2006, 38:228-233.
18. Xu C., Lu Y., Pan Z., Chu W., Luo X., Lin H., et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J. Cell Sci 2007, 120:3045-3052.
19. Uchida Y., Chiyomaru T., Enokida H., Kawakami K., Tatarano S., Kawahara K., et al. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol. Oncol 2013, 31:115-123.
20. Tao J., Wu D., Xu B., Qian W., Li P., Lu Q., et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol. Rep 2012, 27:1967-1975.
21. Cheng Z., Liu F., Wang G., Li Y., Zhang H., Li F. miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer. Cell. Signal 2014, 26:2667-2673.
22. Hou J., Lin L., Zhou W., Wang Z., Ding G., Dong Q., et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011, 19:232-243.
23. Chen W., Han C., Xie B., Hu X., Yu Q., Shi L., et al. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell 2013, 152:467-478.
24. Zhang X., Han S., Kang Y., Guo M., Hong S., Liu F., et al. SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection. Cell. Mol. Immunol 2012, 9:390-398.
25. Qi R., An H., Yu Y., Zhang M., Liu S., Xu H., et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003, 63:8323-8329.
26. Saeki N., Ono H., Sakamoto H., Yoshida T. Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. Cancer Sci 2013, 104:1-8.
27. Shi Y., Hu Z., Wu C., Dai J., Li H., Dong J., et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat. Genet 2011, 43:1215-1218.
28. Liang Q., Yao X., Tang S., Zhang J., Yau T.O., Li X., et al. Integrative identification of epstein-barr virus-associated mutations and epigenetic alterations in gastric cancer. Gastroenterology 2014, 147:1350-1362. e1354.
29. Suva M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
30. Pencheva N., Tavazoie S.F. Control of metastatic progression by microRNA regulatory networks. Nat. Cell Biol 2013, 15:546-554.
31. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat. Rev. Genet 2011, 12:846-860.
32. Duan L.J., Qi J., Kong X.J., Huang T., Qian X.Q., Xu D., et al. miR-133 modulates TGF-beta1-induced bladder smooth muscle cell hypertrophic and fibrotic response: implication for a role of microRNA in bladder wall remodeling caused by bladder outlet obstruction. Cell. Signal 2015, 27:215-227.
33. Muraoka N., Yamakawa H., Miyamoto K., Sadahiro T., Umei T., Isomi M., et al. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. EMBO J. 2014, 33:1565-1581.